This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 1
  • /
  • Calquence approved in Japan to treat relapsed or r...
News

Calquence approved in Japan to treat relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma)-AstraZeneca

Read time: 1 mins
Published:26th Jan 2021
AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL). The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ASCEND Phase III trial and a Phase I trial in Japanese patients, showing Calquence monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus a standard treatment of rituximab, a monoclonal antibody, combined with the physician’s choice of idelalisib, a PI3-kinase inhibitor or bendamustine, a chemotherapy. In the ASCEND trial, Calquence reduced the risk of disease progression or death by 69% (hazard ratio, 0.31; 95% confidence interval, 0.20-0.49, p<0.0001). these results were published in journal of clinical oncology in 2020. see- ghia p, et al." ascend: phase iii, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia [published online ahead of print, 2020 may 27]. j clin oncol. 2020; jco1903355. doi:10.1200 jco.19.03355.>
Condition: CLL/SLL
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.